智通财经APP获悉，先声药业(02096)早盘涨超4%。截至发稿，涨4.31%，报11.86港元，成交额3772.12万港元。
消息面上，9月初，先声药业旗下抗肿瘤创新药公司先声再明宣布，与罗氏就SIM0660达成全球独家授权，取得7500万美元首付款、14.55亿美元里程碑及最高至双位数的分级销售提成。
华泰证券发布研报称，SIM0660为全球FIC，与罗氏在B细胞疾病领域现有管线具备高度配合潜力，有望借助罗氏的全球开发及商业化体系逐步兑现全球价值。同时该笔交易是先声TCE平台继SIM0500后又一重磅出海，连续两笔MNC合作验证了靶点选择与分子设计层面的可复用能力，我们看好平台持续产出高全球价值资产，并实现BD常态化。维持“买入”。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.